Tarek H. Mouhieddine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tarek H. Mouhieddine has a total of 575 co-authors. Here are the top co-authors by number of shared publications:
- Joshua Richter
Icahn School of Medicine at Mount Sinai, New York, USA
39 shared publications - Hearn Jay Cho
Department of Medicine, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA
37 shared publications - Sundar Jagannath
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
37 shared publications - Oliver Van Oekelen
Department of Medicine, Icahn School of Medicine at Mt Sinai , New York City, NY
35 shared publications - Samir Parekh
Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, USA
34 shared publications - Santiago Thibaud
Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
34 shared publications
Latest Publications
- 22 September 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- p. 1-14
Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia
1. Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoma characterized by bone marrow infiltration by monoclonal IgM-producing small B lymphocytes, lymphoplasmacytic cells, and plas...
- 22 September 2026
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- p. 1-14
Current and new approaches to the treatment landscape for adults with Waldenström macroglobulinemia
1. Waldenström macroglobulinemia (WM) is a rare indolent B-cell lymphoma characterized by bone marrow infiltration by monoclonal IgM-producing small B lymphocytes, lymphoplasmacytic cells, and plas...
- 10 September 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (10) , 992-1008
Treatment Decisions in Multiple Myeloma
- 10 September 2026
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 395 (10) , 992-1008
Treatment Decisions in Multiple Myeloma
- 3 September 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2622-2626
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma
- 3 September 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (11) , 2622-2626
Macrophage reprogramming, not CD8 T cell dynamics, characterizes durable disease control following PD-1 blockade in smoldering myeloma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 1: Output of Cox Proportional Hazards Model for Multivariate PFS1 Analysis in HDM-ASCT Recipients with MM (Combined Cohort)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 1: Output of Cox Proportional Hazards Model for Multivariate PFS1 Analysis in HDM-ASCT Recipients with MM (Combined Cohort)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 6: Comparative Per-gene PGV-B Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 6: Comparative Per-gene PGV-B Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 4: Comprehensive characterization of PGV-B/C carriers with multiple myeloma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 8: Assessment of Loss of Heterozygosity (LOH) in Carriers of PGVs in BRCA1 and BRCA2
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 8: Assessment of Loss of Heterozygosity (LOH) in Carriers of PGVs in BRCA1 and BRCA2
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 2: Overall Survival (OS) in PGV-A carriers vs non-carriers
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY FIGURE 2: Overall Survival (OS) in PGV-A carriers vs non-carriers
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 5: Comparative Per-gene PGV-A Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes
SUPPLEMENTARY TABLE 5: Comparative Per-gene PGV-A Burden Analysis in Multiple Myeloma Cohorts versus Non-Cancer gnomAD Control Populations